Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 7/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.49 |
| ▸ | MGLL | Q99685 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | FAAH | O00519 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | XBP1 | P17861 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18019410 | 1.00 | PTGS1 (0.49) | PTGS1PTGS2MGLLSMN1; SMN2FAAH | |
| SCHEMBL18019456 | 0.93 | PTGS1 (0.45) | PTGS1PTGS2MGLLSMN1; SMN2FAAH | |
| SCHEMBL30865058 | 0.90 | PTGS1 (0.49) | PTGS1PTGS2MGLLSMN1; SMN2FAAH | |
| SCHEMBL21697887 | 0.87 | PTGS1 (0.51) | PTGS1PTGS2MGLLSMN1; SMN2FAAH | |
| SCHEMBL15189321 | 0.87 | PTGS1 (0.55) | PTGS1PTGS2MGLLSMN1; SMN2FAAH | |
| SCHEMBL12965566 | 0.87 | PTGS1 (0.51) | PTGS1PTGS2MGLLSMN1; SMN2FAAH | |
| SCHEMBL19514146 | 0.87 | PTGS1 (0.55) | PTGS1PTGS2MGLLSMN1; SMN2FAAH | |
| SCHEMBL16069853 | 0.86 | PTGS1 (0.46) | PTGS1PTGS2MGLLSMN1; SMN2FAAH | |
| SCHEMBL20670908 | 0.86 | PTGS1 (0.46) | PTGS1PTGS2MGLLSMN1; SMN2FAAH | |
| SCHEMBL22267879 | 0.86 | PTGS1 (0.46) | PTGS1PTGS2MGLLSMN1; SMN2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10351593-B2 | Derivatives of dolastatin 10 and uses thereof | NEWBIO THERAPEUTICS, INC. (CN) | 2019-07-16 | — | — | US | disclosed |
| US-10183970-B2 | Cytotoxic tubulysin compounds for conjugation | TUBE PHARMACEUTICALS GMBH (AT) | 2019-01-22 | — | — | US | disclosed |
| US-20180141973-A1 | Derivatives of Dolastatin 10 and Uses Thereof | NEWBIO THERAPEUTICS, INC. (CN) | 2018-05-24 | — | — | US | disclosed |
| US-20180133337-A1 | CALICHEAMICIN CONSTRUCTS AND METHODS OF USE | ABBVIE STEMCENTRX LLC (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351593-B2 | Derivatives of dolastatin 10 and uses thereof | PCSK9, DDOST, DHCR7 | PTGS1 1990/4885PTGS2 2410/4885MGLL 507/4885 |
| US-20180141973-A1 | Derivatives of Dolastatin 10 and Uses Thereof | PCSK9, DDOST, DHCR7 | PTGS1 1990/4885PTGS2 2410/4885MGLL 507/4885 |
| US-10183970-B2 | Cytotoxic tubulysin compounds for conjugation | NGLY1, TEKT1, TWF2 | PTGS1 4605/4885PTGS2 4793/4885MGLL 4787/4885 |
| US-20180133337-A1 | CALICHEAMICIN CONSTRUCTS AND METHODS OF USE | CALD1, CALR, CLSPN | PTGS1 3125/4885PTGS2 3593/4885MGLL 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.